Though many excited traders had hoped to see the bidding war continue between Valeant Pharmaceuticals (BHC -2.17%) and Merz over Obagi Medical Products (NASDAQ: OMPI) and a subsequent run-up in the stock price of the smaller dermatological products maker, Merz has now walked away from the table, leaving the highly acquisitive Valeant the victor. In this video, Motley Fool health care analyst David Williamson gives us some background on these companies and tells us how Valeant plans to profit from the deal, and describes for investors why this is a win both for Obagi and for Valeant.
This Bidding War Was a Bidding Skirmish
By Dave Williamson
-
Apr 9, 2013 at 3:16PM
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The bidding war for Obagi Medical Products is over, and everyone's a winner.
Stocks Mentioned

Bausch Health Companies Inc.
BHC
$9.93
(-2.17%)
$0.22
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles

Better Buy: Moderna or Novavax?

Buying These 5 Dividend Stocks Can Make You Nearly $33,000 in Passive Income

Why Cellectis' Shares Rose 22.7% This Week

Why Pfizer Stock Is Rising Today While Moderna and Novavax Are Sliding

This Safe Stock Is Dirt Cheap -- and It's Beating the Market
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.